Prospective use of amniotic mesenchymal stem cell metabolite products for tissue regeneration
Open Access
- 9 February 2023
- journal article
- review article
- Published by Springer Nature in Journal of Biological Engineering
- Vol. 17 (1) , 1-14
Abstract
Chronic disease can cause tissue and organ damage constituting the largest obstacle to therapy which, in turn, reduces patients’ quality-adjusted life-year. Degenerative diseases such as osteoporosis, Alzheimer’s disease, Parkinson’s disease, and infectious conditions such as hepatitis, cause physical injury to organs. Moreover, damage resulting from chronic conditions such as diabetes can also culminate in the loss of organ function. In these cases, organ transplantation constitutes the therapy of choice, despite the associated problems of immunological rejection, potential disease transmission, and high morbidity rates. Tissue regeneration has the potential to heal or replace tissues and organs damaged by age, disease, or trauma, as well as to treat disabilities. Stem cell use represents an unprecedented strategy for these therapies. However, product availability and mass production remain challenges. A novel therapeutic alternative involving amniotic mesenchymal stem cell metabolite products (AMSC-MP) has been developed using metabolites from stem cells which contain cytokines and growth factors. Its potential role in regenerative therapy has recently been explored, enabling broad pharmacological applications including various gastrointestinal, lung, bladder and renal conditions, as well as the treatment of bone wounds, regeneration and skin aging due to its low immunogenicity and anti-inflammatory effects. The various kinds of growth factors present in AMSC-MP, namely bFGF, VEGF, TGF-β, EGF and KGF, have their respective functions and activities. Each growth factor is formed by different proteins resulting in molecules with various physicochemical properties and levels of stability. This knowledge will assist in the manufacture and application of AMSC-MP as a therapeutic agent.Keywords
Funding Information
- Ministry of Education, Culture, Research and Technology of the Republic of Indonesia (No. 1554/UN3.15/PT/2021)
This publication has 98 references indexed in Scilit:
- Thermal Stability of Fibroblast Growth Factor Protein Is a Determinant Factor in Regulating Self-Renewal, Differentiation, and Reprogramming in Human Pluripotent Stem CellsStem Cells, 2012
- TGF-β and BMP Signaling in Osteoblast Differentiation and Bone FormationInternational Journal of Biological Sciences, 2012
- The discovery of placenta growth factor and its biological activityExperimental & Molecular Medicine, 2012
- Risk factors in the development of stem cell therapyJournal of Translational Medicine, 2011
- Oral protein delivery: Current status and future prospectReactive and Functional Polymers, 2011
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- Keratinocyte Growth Factor Improves Repair in the Injured Tracheal EpitheliumAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic ratsEuropean Respiratory Journal, 2007
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- Growth Factors in Bladder Wound HealingJournal of Urology, 1997